Ceftaroline fosamil

Generic Name: Ceftaroline fosamil

Brand Names: Teflaro, Zinforo

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₁N_₈O_₈PS_₄

CAS Number: 229016-73-3

Unique Ingredient Identifier: 7P6FQA5D21

Background: Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria:

Acute bacterial skin and skin structure infections.

Community-acquired bacterial pneumonia.

Indication: Ceftaroline fosamil is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms.

Associated Conditions: Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP)

Associated Therapies: -

Clinical Trials

Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis

Phase 4

Active, not recruiting

Conditions: Cystic Fibrosis

Interventions: Drug: Ceftaroline

First Posted Date: 2018-12-11

Last Posted Date: 2024-11-20

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 24

Registration Number: NCT03771313

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Normal or Augmented Renal Clearance

Phase 1

Completed

Conditions: Pneumonia

Interventions: Drug: Ceftaroline

First Posted Date: 2017-01-20

Last Posted Date: 2019-03-11

Lead Sponsor: Poitiers University Hospital

Target Recruit Count: 18

Registration Number: NCT03025841

Locations: 🇫🇷
CHU poitiers, Poitiers, France

Antibiotic Prophylaxis in Open Fractures

Phase 4

Conditions: Open Fractures

Interventions: Drug: Ceftaroline

First Posted Date: 2016-10-18

Last Posted Date: 2016-10-28

Lead Sponsor: Olayemi Osiyemi MD

Target Recruit Count: 50

Registration Number: NCT02937181

Locations: 🇺🇸
Triple O Research Institute PA, West Palm Beach, Florida, United States

Penetration of Ceftaroline Into Cerebrospinal Fluid(CSF)

Phase 1

Completed

Conditions: Meningitis
Ventriculitis

Interventions: Drug: Ceftaroline fosamil

First Posted Date: 2016-06-21

Last Posted Date: 2024-02-21

Lead Sponsor: Centre Hospitalier Universitaire Dijon

Target Recruit Count: 10

Registration Number: NCT02806882

Locations: 🇫🇷
CHU Dijon, Dijon, France

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia, Influenza, COVID-19

Interventions: Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Ceftriaxone
Drug: Moxifloxacin or Levofloxacin
Drug: Extended course macrolide
Drug: Fixed-duration Hydrocortisone
Drug: Five-days oseltamivir
Drug: Lopinavir / Ritonavir
Biological: Convalescent plasma
Drug: Angiotensin converting enzyme inhibitor
Drug: Nirmatrelvir/ritonavir
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: Interferon beta-1a
Drug: Vitamin C
Drug: Simvastatin
Drug: Aspirin
Drug: Eritoran
Drug: Cysteamine
Drug: Imatinib
Drug: Shock-dependent hydrocortisone
Drug: Ten-days oseltamivir
Drug: P2Y12 inhibitor
Drug: Angiotensin Receptor Blockers
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Piperacillin-tazobactam
Drug: Hydroxychloroquine
Drug: Anakinra
Drug: Apremilast
Drug: Baricitinib
Drug: Remdesivir
Drug: Fixed-duration higher dose Hydrocortisone
Drug: Hydroxychloroquine + lopinavir/ritonavir
Drug: Intermediate dose thromboprophylaxis
Drug: Nirmatrelvir/ritonavir + remdesivir
Drug: ARB + DMX-200
Drug: Ceftaroline
Drug: Baloxavir Marboxil
Drug: Tocilizumab
Drug: Amoxicillin-clavulanate
Drug: Fixed-duration dexamethasone
Drug: Five-days oseltamivir + baloxavir marboxil
Drug: Continuation of therapeutic dose anticoagulation
Drug: Ivermectin
Drug: Sarilumab
Drug: Ten-days oseltamivir + baloxavir marboxil

First Posted Date: 2016-04-13

Last Posted Date: 2024-07-12

Lead Sponsor: UMC Utrecht

Target Recruit Count: 20000

Registration Number: NCT02735707

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸
University of Illinois Health, Chicago, Illinois, United States
🇦🇺
Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

Phase 4

Completed

Conditions: Bacteremia

Interventions: Drug: Daptomycin
Drug: Vancomycin
Drug: Ceftaroline

First Posted Date: 2016-01-21

Last Posted Date: 2018-02-01

Lead Sponsor: Sharp HealthCare

Target Recruit Count: 40

Registration Number: NCT02660346

Locations: 🇺🇸
Sharp Grossmont Hospital, La Mesa, California, United States
🇺🇸
Sharp Memorial Hospital, San Diego, California, United States

Ceftaroline Diffusion Into Cerebrospinal Fluid of Children

Phase 1

Conditions: Cerebrospinal Fluid Shunts
Ventriculoperitoneal Shunt

Interventions: Drug: Ceftaroline

First Posted Date: 2015-11-09

Last Posted Date: 2018-10-04

Lead Sponsor: Basim Asmar

Target Recruit Count: 12

Registration Number: NCT02600793

Locations: 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

Phase 4

Completed

Conditions: Staphylococcal Skin Infections
Skin Diseases, Infectious

Interventions: Drug: Ceftaroline
Drug: Vancomycin

First Posted Date: 2015-10-21

Last Posted Date: 2016-11-01

Lead Sponsor: Wayne State University

Target Recruit Count: 174

Registration Number: NCT02582203

Locations: 🇺🇸
St. John Hospital and Medical Center, Detroit, Michigan, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Detroit Medical Center, Detroit, Michigan, United States

Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis

Phase 2

Terminated

Conditions: Late-onset Sepsis

Interventions: Drug: Ceftaroline Fosamil
Drug: Ampicillin
Drug: Aminoglycoside

First Posted Date: 2015-04-23

Last Posted Date: 2018-09-13

Lead Sponsor: Pfizer

Target Recruit Count: 11

Registration Number: NCT02424734

Locations: 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇭🇺
Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak, Gyermek-, Koraszulott es Csecsemoosztaly, Budapest, Hungary
🇭🇺
Egyesitett Szent Istvan es Szent Laszlo Korhaz - Rendelointezet, Gyermekinfektologiai Osztaly, Budapest, Hungary

and more 1 locations

Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

Phase 1

Completed

Conditions: Hematogenously Acquired Staphylococcus Aureus Osteomyelitis
Bone Infection
Osteomyelitis

Interventions: Drug: Ceftaroline Fosamil

First Posted Date: 2015-01-12

Last Posted Date: 2021-11-02

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 11

Registration Number: NCT02335905

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy